Dyne Therapeutics, Inc. (DYN) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 1 Strong Buy, 11 Buy, 1 Hold.
The consensus price target is $37.60 (low: $23.00, high: $60.00), representing an upside of 89.8% from the current price $19.81.
Analysts estimate Earnings Per Share (EPS) of $-3.47 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.37 vs est $-3.47 (beat +2.8%). 2025: actual $-3.47 vs est $-3.50 (beat +0.9%). Analyst accuracy: 98%.
DYN Stock — 12-Month Price Forecast
$37.60
▲ +89.80% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Dyne Therapeutics, Inc., the average price target is $37.60, with a high forecast of $60.00, and a low forecast of $23.00.
The average price target represents a +89.80% change from the last price of $19.81.
Highest Price Target
$60.00
Average Price Target
$37.60
Lowest Price Target
$23.00
DYN Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Dyne Therapeutics, Inc. in the past 3 months
EPS Estimates — DYN
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.37
vs Est –$3.47
▲ 2.8% off
2025
Actual –$3.47
vs Est –$3.50
▲ 0.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — DYN
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
